A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects
✍ Scribed by Peng, S; Tomson, T T; Trimble, C; He, L; Hung, C-F; Wu, T-C
- Book ID
- 110039702
- Publisher
- Nature Publishing Group
- Year
- 2005
- Tongue
- English
- Weight
- 333 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0969-7128
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The development of a vaccine that would be capable of preventing or curing the (pre)cancerous lesions induced by genital oncogenic human papillomaviruses (HPVs) is the focus of much research. Many studies are presently evaluating vaccines based on the viral E6 and E7 oncoproteins, both of which are
## Abstract ## Background The E7 oncoprotein of human papillomavirus type 16 (HPV16) is frequently used as a model tumor‐associated antigen. Its immunogenicity has been substantially enhanced by fusion with several proteins of various origins and functions. Different mechanisms have been responsib
## Abstract Human papillomavirus (HPV) infection is associated with cervical cancer. The E2 and E1 papillomavirus proteins are expressed at the early stage of infection and regulate DNA replication. The E2 protein activates and represses transcription from different HPVs promoters. At some stage wh
## Abstract The mounting of a specific immune response against the human papillomavirus type 16 E7 protein (HPV16 E7) is important for eradication of HPV16 E7‐expressing cancer cells from the cervical mucosa. To induce a mucosal immune response by oral delivery of the E7 antigen, we expressed the H